Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Clinical trial NCT03409614 · COMPLETED
Trial details
- NCT number
- NCT03409614
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-06
- Primary completion
- 2025-02-27
- Enrollment
- 789
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.